Bristol Myers Squibb Company $BMY Position Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 274,249 shares of the biopharmaceutical company’s stock after purchasing an additional 19,441 shares during the period. Oppenheimer & Co. Inc.’s holdings in Bristol Myers Squibb were worth $17,113,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Primecap Management Co. CA purchased a new position in Bristol Myers Squibb during the second quarter worth $1,436,115,000. Legal & General Group Plc acquired a new position in shares of Bristol Myers Squibb in the second quarter worth $980,862,000. BlackRock Inc. lifted its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp lifted its position in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Finally, Caisse de depot et placement du Quebec acquired a new stake in shares of Bristol Myers Squibb during the second quarter valued at $243,646,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $61.56 on Tuesday. The company has a market cap of $125.75 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.31 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The business has a fifty day simple moving average of $63.20 and a 200-day simple moving average of $59.79.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm posted $1.46 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.51 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Analyst Ratings Changes

A number of analysts recently commented on BMY shares. Wells Fargo & Company dropped their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 13th. Cantor Fitzgerald reduced their target price on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Raymond James Financial began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $65.50.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.